Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines

Cancer Letters

Volumn 347, Issue 2, 2014, Pages 196-203

  Katanasaka, Yasufumi ^a,b   Kodera, Yasuo ^a   Yunokawa, Mayu ^a   Kitamura, Yuka ^a   Tamura, Tomohide ^a   Koizumi, Fumiaki ^a,c  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

BGT226; Combination therapy; Gefitinib; NSCLC; PI3K AKT mTOR signal axis

Indexed keywords

BGT226; COMBINATION THERAPY; GEFITINIB; NSCLC; PI3K/AKT/MTOR SIGNAL AXIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL LINE, TUMOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; QUINAZOLINES; QUINOLINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898400190     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.025     Document Type: Article

References (35)

1. Takano T., Fukui T., Ohe Y., Tsuta K., Yamamoto S., Nokihara H., Yamamoto N., Sekine I., Kunitoh H., Furuta K., Tamura T. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J. Clin. Oncol. 2008, 26:5589-5595.
2. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., Majem M., Lopez-Vivanco G., Isla D., Provencio M., Insa A., Massuti B., Gonzalez-Larriba J.L., Paz-Ares L., Bover I., Garcia-Campelo R., Moreno M.A., Catot S., Rolfo C., Reguart N., Palmero R., Sanchez J.M., Bastus R., Mayo C., Bertran-Alamillo J., Molina M.A., Sanchez J.J., Taron M. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 2009, 361:958-967.
3. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
4. Stoppoloni D., Canino C., Cardillo I., Verdina A., Baldi A., Sacchi A., Galati R. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol. Cancer 2010, 9:27.
5. Choi Y.J., Rho J.K., Jeon B.S., Choi S.J., Park S.C., Lee S.S., Kim H.R., Kim C.H., Lee J.C. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemother. Pharmacol. 2009, 66:381-388.
6. Okabe T., Okamoto I., Tsukioka S., Uchida J., Hatashita E., Yamada Y., Yoshida T., Nishio K., Fukuoka M., Janne P.A., Nakagawa K. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 2009, 15:907-913.
7. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discovery 2009, 8:627-644.
8. Zhao L., Vogt P.K. Class I PI3K in oncogenic cellular transformation. Oncogene 2008, 27:5486-5496.
9. Yin Y., Shen W.H. PTEN: a new guardian of the genome. Oncogene 2008, 27:5443-5453.
10. Markman B., Atzori F., Perez-Garcia J., Tabernero J., Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann. Oncol. 2010, 21:683-691.
11. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Velculescu V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
12. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 2004, 22:2954-2963.
13. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
14. Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., Hostetter G., Boguslawski S., Moses T.Y., Savage S., Uhlik M., Lin A., Du J., Qian Y.W., Zeckner D.J., Tucker-Kellogg G., Touchman J., Patel K., Mousses S., Bittner M., Schevitz R., Lai M.H., Blanchard K.L., Thomas J.E. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-444.
15. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
16. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28:1075-1083.
17. Howes A.L., Chiang G.G., Lang E.S., Ho C.B., Powis G., Vuori K., Abraham R.T. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol. Cancer Ther. 2007, 6:2505-2514.
18. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., Garcia-Echeverria C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008.
19. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., Maira M., Garcia-Echeverria C., Parra J.L., Arribas J., Baselga J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68:8022-8030.
20. Koizumi F., Shimoyama T., Taguchi F., Saijo N., Nishio K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int. J. Cancer 2005, 116:36-44.
21. Turke A.B., Zejnullahu K., Wu Y.L., Song Y., Dias-Santagata D., Lifshits E., Toschi L., Rogers A., Mok T., Sequist L., Lindeman N.I., Murphy C., Akhavanfard S., Yeap B.Y., Xiao Y., Capelletti M., Iafrate A.J., Lee C., Christensen J.G., Engelman J.A., Janne P.A. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
22. Katanasaka Y., Ishii T., Asai T., Naitou H., Maeda N., Koizumi F., Miyagawa S., Ohashi N., Oku N. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. Int. J. Cancer 2010, 127:2685-2698.
23. Zhao L., Wientjes M.G., Au J.L. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin. Cancer Res. 2004, 10:7994-8004.
24. Tallarida R.J. An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 2006, 319:1-7.
25. Song L., Morris M., Bagui T., Lee F.Y., Jove R., Haura E.B. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006, 66:5542-5548.
26. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J.J., Chewaskulyong B., Jiang H., Duffield E.L., Watkins C.L., Armour A.A., Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
27. Okabe T., Okamoto I., Tsukioka S., Uchida J., Iwasa T., Yoshida T., Hatashita E., Yamada Y., Satoh T., Tamura K., Fukuoka M., Nakagawa K. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol. Cancer Ther. 2008, 7:599-606.
28. Noro R., Gemma A., Miyanaga A., Kosaihira S., Minegishi Y., Nara M., Kokubo Y., Seike M., Kataoka K., Matsuda K., Okano T., Yoshimura A., Kudoh S. PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int. J. Oncol. 2007, 31:1157-1163.
29. Ihle N.T., Paine-Murrieta G., Berggren M.I., Baker A., Tate W.R., Wipf P., Abraham R.T., Kirkpatrick D.L., Powis G. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol. Cancer Ther. 2005, 4:1349-1357.
30. Rosell R., Molina M.A., Costa C., Simonetti S., Gimenez-Capitan A., Bertran-Alamillo J., Mayo C., Moran T., Mendez P., Cardenal F., Isla D., Provencio M., Cobo M., Insa A., Garcia-Campelo R., Reguart N., Majem M., Viteri S., Carcereny E., Porta R., Massuti B., Queralt C., de Aguirre I., Sanchez J.M., Sanchez-Ronco M., Mate J.L., Ariza A., Benlloch S., Sanchez J.J., Bivona T.G., Sawyers C.L., Taron M. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin. Cancer Res. 2011, 17:1160-1168.
31. Faber A.C., Li D., Song Y., Liang M.C., Yeap B.Y., Bronson R.T., Lifshits E., Chen Z., Maira S.M., Garcia-Echeverria C., Wong K.K., Engelman J.A. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc. Natl. Acad. Sci. USA 2009, 106:19503-19508.
32. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., Chirieac L.R., Kaur R., Lightbown A., Simendinger J., Li T., Padera R.F., Garcia-Echeverria C., Weissleder R., Mahmood U., Cantley L.C., Wong K.K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
33. Lim K.H., Counter C.M. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 2005, 8:381-392.
34. Janes M.R., Limon J.J., So L., Chen J., Lim R.J., Chavez M.A., Vu C., Lilly M.B., Mallya S., Ong S.T., Konopleva M., Martin M.B., Ren P., Liu Y., Rommel C., Fruman D.A. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med. 2010, 16:205-213.
35. Neal J.W., Sequist L.V. Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Nat. Rev. Clin. Oncol. 2010, 7:71-72.